TY - JOUR
T1 - Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors
AU - Garbett, K. A.
AU - Vereczkei, A.
AU - Kálmán, S.
AU - Wang, L.
AU - Korade, Z.
AU - Shelton, R. C.
AU - Mirnics, K.
N1 - Funding Information:
KM was supported by National Institute of Mental Health Grants R01 MH067234 and R01 MH079299. RCS was supported by National Institute of Mental Health Grants MH01741, MH52339 and MH073630 and a grant from the Brain and Behavior Research Foundation. We are especially grateful to Weining Xu, Senior Manager at Qiagen, for her invaluable guidance in the use of the miRNome arrays. We thank the Vantage Molecular Biology Core at Vanderbilt for their help in performing the microarray and miRNome array studies. We offer our sincere appreciation to Dr Marla Perna, who provided constructive comments on the manuscript preparation.
PY - 2015
Y1 - 2015
N2 - Major depressive disorder (MDD) is increasingly viewed as interplay of environmental stressors and genetic predisposition, and recent data suggest that the disease affects not only the brain, but the entire body. As a result, we aimed at determining whether patients with major depression have aberrant molecular responses to stress in peripheral tissues. We examined the effects of two metabolic stressors, galactose (GAL) or reduced lipids (RL), on the transcriptome and miRNome of human fibroblasts from 16 pairs of patients with MDD and matched healthy controls (CNTR). Our results demonstrate that both MDD and CNTR fibroblasts had a robust molecular response to GAL and RL challenges. Most importantly, a significant part (messenger RNAs (mRNAs): 26-33%; microRNAs (miRNAs): 81-90%) of the molecular response was only observed in MDD, but not in CNTR fibroblasts. The applied metabolic challenges uncovered mRNA and miRNA signatures, identifying responses to each stressor characteristic for the MDD fibroblasts. The distinct responses of MDD fibroblasts to GAL and RL revealed an aberrant engagement of molecular pathways, such as apoptosis, regulation of cell cycle, cell migration, metabolic control and energy production. In conclusion, the metabolic challenges evoked by GAL or RL in dermal fibroblasts exposed adaptive dysfunctions on mRNA and miRNA levels that are characteristic for MDD. This finding underscores the need to challenge biological systems to bring out disease-specific deficits, which otherwise might remain hidden under resting conditions.
AB - Major depressive disorder (MDD) is increasingly viewed as interplay of environmental stressors and genetic predisposition, and recent data suggest that the disease affects not only the brain, but the entire body. As a result, we aimed at determining whether patients with major depression have aberrant molecular responses to stress in peripheral tissues. We examined the effects of two metabolic stressors, galactose (GAL) or reduced lipids (RL), on the transcriptome and miRNome of human fibroblasts from 16 pairs of patients with MDD and matched healthy controls (CNTR). Our results demonstrate that both MDD and CNTR fibroblasts had a robust molecular response to GAL and RL challenges. Most importantly, a significant part (messenger RNAs (mRNAs): 26-33%; microRNAs (miRNAs): 81-90%) of the molecular response was only observed in MDD, but not in CNTR fibroblasts. The applied metabolic challenges uncovered mRNA and miRNA signatures, identifying responses to each stressor characteristic for the MDD fibroblasts. The distinct responses of MDD fibroblasts to GAL and RL revealed an aberrant engagement of molecular pathways, such as apoptosis, regulation of cell cycle, cell migration, metabolic control and energy production. In conclusion, the metabolic challenges evoked by GAL or RL in dermal fibroblasts exposed adaptive dysfunctions on mRNA and miRNA levels that are characteristic for MDD. This finding underscores the need to challenge biological systems to bring out disease-specific deficits, which otherwise might remain hidden under resting conditions.
UR - http://www.scopus.com/inward/record.url?scp=84981194461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981194461&partnerID=8YFLogxK
U2 - 10.1038/tp.2015.14
DO - 10.1038/tp.2015.14
M3 - Article
C2 - 25756806
AN - SCOPUS:84981194461
SN - 2158-3188
VL - 5
JO - Translational Psychiatry
JF - Translational Psychiatry
IS - 3
M1 - A523
ER -